Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ISIS 104838 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ISIS 104838 | DRUG | - |
Inclusion Criteria 1. Age \>/= 18 years. 2. Rheumatoid arthritis for \>/= 6 months. 3. Active disease as defined by \>/= 6 swollen and \>/= 9 tender joints, AND an abnormal C-reactive protein or Westergren Erythrocyte Sedimentation Rate lab test, OR Morning Stiffness \>/= 1 hour. 4. Use of at least...
Top 20 of 28 competitors
ISIS 104838 is an investigational drug being studied for the treatment of active rheumatoid arthritis. It is an inhibitor of tumor necrosis factor, a protein involved in inflammation. The drug is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ISIS 104838 targets tumor necrosis factor, a cytokine that plays a key role in the inflammatory process of rheumatoid arthritis. By inhibiting tumor necrosis factor, the drug aims to reduce inflammation and potentially alleviate symptoms associated with the condition.
ISIS 104838 is being developed by Ionis Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol IONS. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for rheumatoid arthritis.
ISIS 104838 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The drug is being studied in patients with active rheumatoid arthritis to assess its potential therapeutic effects.
ISIS 104838 has been studied in a Phase 2 clinical trial with the identifier NCT00048321. This completed trial enrolled 160 participants with active rheumatoid arthritis and was conducted in the United States and Canada. The study was randomized and double-blind, though it did not use a control group.
ISIS 104838 is also known by its chemical name and is sometimes referred to as an antisense inhibitor of tumor necrosis factor. No alternative brand names have been established for this investigational drug, as it is still in clinical development.